NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis $3.49 +0.35 (+11.15%) Closing price 10/16/2026 03:54 PM EasternExtended Trading$3.50 +0.01 (+0.29%) As of 10/16/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Adial Pharmaceuticals Stock (NASDAQ:ADIL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adial Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.07▼$3.6650-Day Range$3.00▼$7.1252-Week Range$1.31▼$9.75Volume56,445 shsAverage Volume43,526 shsMarket Capitalization$9.16 millionP/E RatioN/ADividend YieldN/APrice Target$8.33Consensus RatingHold Company Overview Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company uses a genetically targeted approach intended to identify patients who may be more likely to respond to specific therapies. Adial’s lead product candidate, AD04, is an investigational formulation of ondansetron, a selective serotonin-3 receptor antagonist. It is being developed for the treatment of alcohol use disorder, with the goal of reducing alcohol consumption and supporting abstinence in genetically selected patient populations. The company has also evaluated the potential application of its platform in other addictive disorders, including smoking cessation. Founded in 2011, Adial Pharmaceuticals is headquartered in Charlottesville, Virginia. Its development programs are subject to clinical testing and regulatory review, and the company’s therapies are not approved for commercial use unless and until applicable regulatory requirements are satisfied. William M. Stilley has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Adial Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreADIL MarketRank™: 2.790636159235 of 5 starsAdial Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingAdial Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAdial Pharmaceuticals has a consensus price target of $8.33, representing about 138.8% upside from its current price of $3.49.Amount of Analyst CoverageAdial Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Adial Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adial Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.59% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 4.28.Change versus previous monthShort interest in Adial Pharmaceuticals has recently decreased by 12.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.67 News SentimentAdial Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adial Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders8.00% of the stock of Adial Pharmaceuticals is held by insiders.Percentage Held by Institutions16.41% of the stock of Adial Pharmaceuticals is held by institutions.Read more about Adial Pharmaceuticals' insider trading history. Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADIL Stock News HeadlinesAdial Pharmaceuticals, Inc. Announces Appointment of David Rubenstein, M.D., Ph.D. as Chief ScientistOctober 16 at 1:02 PM | marketscreener.comMAdial Pharmaceuticals Appoints AhR Drug Development Veteran David Rubenstein as Chief Scientist to Advance AT177 for Ulcerative ColitisOctober 16 at 7:31 AM | quiverquant.comQThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 18 at 1:00 AM | Behind the Markets (Ad)Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative ColitisOctober 16 at 7:00 AM | globenewswire.comAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)September 30, 2026 | globenewswire.comAdial Pharmaceuticals Announces Board AppointmentsSeptember 18, 2026 | marketscreener.comMAdial Shareholders Approve Key Proposals, Meeting AdjournedSeptember 18, 2026 | tipranks.comAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)August 25, 2026 | globenewswire.comSee More Headlines ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed this year? Adial Pharmaceuticals' stock was trading at $5.50 on January 1st, 2026. Since then, ADIL stock has decreased by 36.5% and is now trading at $3.49. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its quarterly earnings data on Friday, August, 14th. The company reported ($11.25) EPS for the quarter, missing analysts' consensus estimates of ($1.03) by $10.22. When did Adial Pharmaceuticals' stock split? Adial Pharmaceuticals's stock reverse split on Friday, February 6th 2026.The 1-25 reverse split was announced on Tuesday, February 3rd 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $15 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,464,000 shares at a price of $9.00-$11.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include Advanced Micro Devices (AMD), Marvell Technology (MRVL), Palantir Technologies (PLTR), Trade Desk (TTD), Vanda Pharmaceuticals (VNDA), Archer Aviation (ACHR) and Amprius Technologies (AMPX). Company Calendar Last Earnings8/14/2026Today10/18/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 9 days, ADIL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ADIL CIK1513525 Webwww.adial.com Phone(434) 422-9800FaxN/AEmployees6Year Founded2010Price Target and Rating Average Price Target for Adial Pharmaceuticals$8.33 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+138.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($14.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-203.87% Return on Assets-512.41% Debt Debt-to-Equity RatioN/A Current Ratio5.63 Quick Ratio5.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.75 per share Price / Book0.73Miscellaneous Outstanding Shares2,626,000Free Float2,416,000Market Cap$9.16 million OptionableNo Data Beta1.50 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ADIL) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis link won't stay freeThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
